Company Overview of Raptor Pharmaceuticals Corp.
Raptor Pharmaceutical Corp., a biopharmaceutical company, focuses on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The company offers PROCYSBI, a delayed-release capsule, which is used for the management of nephropathic cystinosis in adults, as well as in six years and older children in the United States, in the 28 member states of the European Union, Norway, Liechtenstein, and Iceland. It also provides QUINSAIR, a formulation of the antibiotic drug levofloxacin for the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa in cystic fibrosis patients in Canada and Europe. The company’s clinical development pr...
7 Hamilton Landing
Novato, CA 94949
Founded in 2005
Key Executives for Raptor Pharmaceuticals Corp.
Co-Founder and Chief Scientific Officer
Chief Financial Officer, Executive Vice President and Director
Chief Legal & Compliance Officer, Senior Vice President of Government Affairs and Secretary
Compensation as of Fiscal Year 2017.
Raptor Pharmaceuticals Corp. Key Developments
Horizon Pharmaceutical LLC Files Form 15
Nov 4 16
Horizon Pharmaceutical LLC has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.001 per share.
Raptor Pharmaceuticals Corp. Announces Cessation of Board of Directors; Announces Amendments to Certificate of Incorporation and the Bylaws
Oct 25 16
Raptor Pharmaceutical Corp. entered into an Agreement and Plan of Merger (the Merger Agreement), dated as of September 12, 2016, with Horizon Pharma plc (Parent), and Misneach Corporation and an indirect wholly owned subsidiary of Parent (Merger Sub). As of the Effective Time, each of Julie A. Smith, Gregg Lapointe, Raymond W. Anderson, Suzanne L. Bruhn Ph.D., Richard L. Franklin M.D., Ph.D., Georges Gemayel, Ph.D., Llew Keltner, M.D., Ph.D. and Christopher M. Starr, Ph.D., ceased serving as directors of Raptor, and the directors of Merger Sub as of the Effective Time, consisting of Timothy P. Walbert and Paul W. Hoelscher, became the sole directors of the Surviving Corporation.
In connection with the consummation of the Merger, the certificate of incorporation of Raptor and the bylaws of Raptor were each amended and restated in their entirety.
Raptor Pharmaceutical Intends To File With SEC Certification And Notice Of Termination On Form 15, Requesting Deregistration Of Common Stock
Oct 25 16
Raptor Pharmaceutical Corp. entered into an Agreement and Plan of Merger (Merger Agreement), dated as of September 12, 2016, with Horizon Pharma plc (Parent) and Misneach Corporation (Merger Sub). Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, Merger Sub commenced a tender offer to purchase all of the issued and outstanding shares (Shares) of Raptor’s common stock, par value $0.001 per share (Common Stock), for a purchase price of $9.00 per Share (Offer Price), payable to the holder thereof in cash, without interest and less any applicable withholding taxes, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated as of September 26, 2016 (as amended or supplemented from time to time, the Offer to Purchase), and in the related Letter of Transmittal (as amended or supplemented from time to time, which, together with the Offer to Purchase, constitute the Offer). The Offer and withdrawal rights expired at the end of the day on October 24, 2016. Also on October 25, 2016, pursuant to the terms of the Merger Agreement and in accordance with Section 251(h) of the Delaware General Corporation Law (DGCL), Merger Sub merged with and into Raptor (Merger), with Raptor continuing as the surviving corporation (Surviving Corporation). On October 25, 2016, Raptor Pharmaceutical notified The NASDAQ Global Market (NASDAQ) of the consummation of the Merger and requested that NASDAQ (i) suspend trading of the Common Stock before the opening of trading on October 25, 2016 and (ii) file with the SEC a Form 25 Notification of Removal from Listing and/or Registration to delist and deregister the Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (Exchange Act). Raptor intends to file with the SEC a Certification and Notice of Termination on Form 15, requesting the deregistration of the Common Stock under Section 12(g) of the Exchange Act and the suspension of Raptor’s reporting obligations under Sections 13 and 15(d) of the Exchange Act.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 12, 2016